MYC and hepatocellular carcinoma: Disruption of these molecular pathways occurs throughout the development of HCC, and these miRNAs have the potential to influence multiple therapeutic targets, including P53, RAS/MAPK, WNT/β-catenin, PI3K/AKT/mTOR, MET, MYC, and TGF-β (Hou et al., 2011).